骨巨细胞瘤治疗药物狄诺塞麦效果如何？

Globally, giant cell tumor of bone accounts for approximately 4%-5% of all primary bone tumors. Compared with European and American populations, it is more common in China, accounting for approximately 20% of all primary bone tumors. Although the vast majority of giant cell tumors of bone are benign tumors, if left untreated, they often cause complete destruction of the affected bone, leading to fractures, joint dysfunction, or amputation. The successful development of (Denosumab) has brought good news to patients. So how effective is the treatment drug denosumab (desosumab) for giant cell tumor of bone?

Three randomized-double-blind clinical studies confirmed the safety and efficacy of denosumab (desosumab), with a total of 5,723 patients participating in the studies. These studies compared denosumab (desosumab) with zoledronic acid in patients with breast cancer, prostate cancer, and various other cancers. The studies were designed to measure the time between patients ultimately suffering a fracture or spinal cord compression due to cancer, or requiring radiation or surgery to control pain.

The median delay in SREs in patients with prostate cancer was 21 months and 17 months with zoledronic acid. Zoledronic acid delayed SREs for a median of 26 months in breast cancer patients, whereas denosumab (desosumab) did not achieve this level. In other patients with solid tumors, denosumab and zoledronic acid delayed SREs by similar median times. The main solid tumors of the subjects were non-small cell lung cancer, multiple myeloma, renal cancer and small cell lung cancer. The most serious adverse reactions of denosumab are hypocalcemia and osteonecrosis of the jaw.

Finally, patients are reminded that before choosing denosumab (desosumab) treatment, they need to understand whether they are contraindicated by this drug. (1) Pregnancy: According to animal data, it may cause fetal damage. Pregnancy monitoring programs available (2) Breastfeeding mothers: Breast development and lactation may be impaired. Discontinue drug or breastfeed (3) Pediatric patients: Placebo and effectiveness have not been established (4) Renal impairment: Patients with creatinine clearance less than 30 mL/min or receiving dialysis are at risk for hypocalcemia. If you are a contraindication to the use of denosumab, it is best to discuss with your doctor about changing other anti-cancer drugs for treatment.

Recommended related hot articles: /newsDetail/77995.html